PHARMAC and the statin debacle

New Zealand Medical Journal

Volumn 119, Issue 1236, 2006, Pages

  Ellis, Chris J ^a   White, Harvey ^a  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CERIVASTATIN; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST BENEFIT ANALYSIS; DEATH; DRUG COST; DYSLIPIDEMIA; HEALTH CARE DELIVERY; HEALTH CARE FINANCING; HEART INFARCTION; HIGH RISK PATIENT; HUMAN; ISCHEMIC HEART DISEASE; NEW ZEALAND; PHARMACEUTICAL CARE; REVIEW; RISK REDUCTION; STROKE; SURVIVAL RATE; UNSPECIFIED SIDE EFFECT; ARTICLE; DRUG CONTROL; DRUG SCREENING; ECONOMICS; HEALTH INSURANCE; HYPERCHOLESTEROLEMIA; PUBLIC HEALTH;

DRUG AND NARCOTIC CONTROL; DRUG EVALUATION; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; INSURANCE, PHARMACEUTICAL SERVICES; NATIONAL HEALTH PROGRAMS; NEW ZEALAND;

EID: 33745614039     PISSN: 11758716     EISSN: 11758716     Source Type: Journal    
DOI: None     Document Type: Review

References (67)

1. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. BMJ. 2003;326:1423-7.
2. Grundy SM, Cleeman JI, Merz CNB, et al. Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel 3 Guidelines. J Am Coll Cardiol 2004;44:720-732.
3. Cholesterol Treatment Trialists' (CTT) Collaborators. Efficacy and safety of cholesterollowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005;366:1267-1278
4. Cannon CP, Braunwald E, McCabe CH, et al. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495-1504.
5. Nissen SE, Tuzcu EM, Schoenhagen P. et al. REVERSAL Investigators. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: A randomized controlled trial. JAMA 2004;291:1071-1080.
6. Topol EJ. Intensive Statin Therapy - A Sea Change in Cardiovascular Prevention. N Eng J Med 2004;350:1562-1564.
7. The Assessment and Management of Cardiovascular Risk. Ministry of Health Guidelines Group December 2003 Guideline.
8. Scott RS, Lintott CJ, Wilson MJ. Simvastatin and side effects. N Z Med J 1991;104:493-495.
9. French JK, White HD, Greaves SC. Simvastatin therapy for hypercholesterolaemia in patients with coronary heart disease. N Z Med J 1990;103:41-43.
10. Thomson GR. Angiographic trials of lipid-lowering therapy: End of an era. Br Heart J1995;74:343-7.
11. Scandinavian Simvastatin Survival Study Group. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease (4S). Lancet 1994;344:1383-9.
12. Sacks FM, Pfeffer MA, Moye LA et al. The effect of pravastatin on coronary heart disease. N Engl J Med 1996;335:1001-9.
13. Pharmaceutical Management Agency Ltd (PHARMAC). New Zealand Pharmaceutical Schedule - December 1996. Wellington.
14. Mann JI, Crooke M, Fear H et al. Guidelines for detection and management of dyslipidaemia. N Z Med J 1993; 106:133-142.
15. Mann J, Chisholm A, Crooke M et al. Management of patients with dyslipidaemia. N Z Med J 1995; 108:444.
16. Ellis CJ, French JK, White HD et al. Results of percutaneous coronary angioplasty in Patients <40 years of age. Am J Cardiol. 1998;82:135-139.
17. French JK, Scott DS, Whitlock RML et al. Late outcome after coronary graft surgery in Patients <40 years old. Circulation 1995;92 Suppl 2:14-19.
18. Ellis CJ, Zambanini A, French JK et al. Inadequate control of lipid levels in patients with a previous myocardial infarction. N Z Med J 1998; 111:464-467.
19. Pharmaceutical management Agency Ltd (PHARMAC). New Zealand Pharmaceutical Schedule - August 1997. Wellington.
20. Ose L, Scott R. Double-blind comparison of the efficacy and tolerability of simvastatin and fluvastatin in patients with primary hypercholesterolaemia. Clin Drug Invest 1995; 10: 127-38.
21. Ellis CJ, McHaffie D, Elliott J. Wilkins G. Statins and Pharmac. N Z Med J 1998; 111:38.
22. Bagg W, Braatvedt G. Fluvastatin: What is the evidence? N Z Med J 1997;110:321-322.
23. Allen P. Fluvastatin. N Z Med J 197; 110:403.
24. Ellis CJ, McHaffie D. Elliott J, Wilkins G. Statins and Pharmac. N Z Med J 1999; 112:55.
25. Mann J, Scott R. Lipid-modifying drugs. N Z Med J 1998; 111:285-7.
26. Ellis CJ, O'Meeghan TO, Hamer AW et al. Evidence based strategies for secondary prevention of ischaemic heart disease: Time to improve clinical practice. N Z Med J 1998; 111:170-2.
27. Bennett W. Fluvastatin. N Z Med J 1997:110-403.
28. Bennett W. Statins. N Z Med J 1998; 111: 194-195.
29. Bennett W, McNee W. PHARMAC and statins. N Z Med J 1998;111:439.
30. McNee W, Smart T. Statins and Pharmac. N Z Med J 1999; 112:55-6.
31. Mann S, Clare G. The effects of changing statins on cholesterol levels. N Z Med J 1999; 112:260.
32. Thomas MC, Mann J, Williams S. The impact of reference pricing on clinical lipid control. N Z Med J 1998; 111:292-294.
33. Thomas MC, Mann J, Williams S. PHARMAC and statins. N Z Med J 1998; 111;439-440.
34. Thomas M, Mann J. Increased thrombotic vascular events after change of statin. Lancet 1998;352;1830-1831.
35. Jones P, Kafonek S, Laurora I, Hunninghale D, for the CURVES Investigators. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (The CURVES Study). Am J Cardiol 1998;81:582-7.
36. Campeau L, Enjalbert M, Lespérance J et al. The relation of risk factors to the development of atherosclerosis in saphenous vein bypass grafts and the progression of disease in the native circulation: A study ten years after aorto-coronary bypass surgery. N Eng J, Med 1984;311:1329-32.
37. Blankenhorn DH, Nessim SA, Johnson RL et al. Beneficial effects of combined colestipolniacin therapy on coronary atherosclerosis and coronary venous bypass grafts. JAMA 1987;257:3233-40.
38. The Post Coronary Artery Bypass Grafting Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous vein coronary artery bypass grafts. N Engl J Med 1997;336:153-62.
39. The LIPID Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Eng J Med 1998;339:1349-1357.
40. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: The LIPID trial follow-up. Lancet 2002;359:1379-1387.
41. White HD, Simes RJ, Anderson NE et al. Pravastatin therapy and the risk of stroke. N Engl J Med, 2000;343:317-326.
42. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial. Lancet 2002;360:7-22.
43. Pharmaceutical Management Agency. PHARMAC annual review 1998. Wellington: 1998.
44. Pharmaceutical Management Agency. PHARMAC annual review 1999. Wellington: 1999.
45. Special Authority Form: Statins. Pharmaceutical Management Agency. December 1998.
46. Ellis CJ, Scott R. Cardiovascular disease and lipid management in New Zealand: Progress at last! N Z Med J 2002;115:197-199.
47. Schwartz GG, Olsson AG, Ezekowitz MD et al. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acAte coronary syndromes: The MIRACL study: a randomized controlled trial JAMA 2001;285:1711-1718.
48. Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 2003;361:1149-1158.
49. Athyros VG, Papageorgiou AA, Mercouris BR et al. Treatment with atorvastatin to the National Cholesterol Educational Program Goal versus 'Usual' Care in secondary coronary heart disease prevention. The Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study. Curr Med Res and Opin 2002; 18:220-228.
50. Moodie P. Changes to subsidy levels for statins. PHARMAC letter. 11 May 2004.
51. Hansard. 13 May 2006. Questions to ministers: Question Number 11. Wellington, New Zealand.
52. Crotty M, Pluncket S. Radio New Zealand 'Morning Report Interview. 12 May 2006. Newsmonitor Services Limited.
53. Nissen SE. High-Dose Statins in Acute Coronary Syndromes. Not Just Lipid Levels. JAMA 2004;292:1367.
54. Waters DD. Safety of High-Dose Atorvastatin Therapy. Am J Cardiol 2005;96[suppl]:69F-75F.
55. Abbott T. Minister of Health and Ageing Press Release. 15 July 2005.
56. Koren MJ, Hunninghake DB on behalf of the ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics. The Alliance study. J Am Coll Cardiol 2004;44:1772-1779.
57. Colhoun HM, Beeteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS); multicentre randomised placebo-controlled trial. Lancet 2004;364:685-696.
58. Pederson TR, Faergeman O, Kastelein JP et al. High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial Infarction. The IDEAL Study: A Randomized Controlled Trial. JAMA 2005;294:2437-2445.
59. Gagne C, Bays HE, Weiss SR et al. Efficacy and safety of Ezetimibe Added to Ongoing Statin Therapy for Treatment of Patients with Primary Hypercholesterolemia. Am J Cardiol 2002;90:1084-1091.
60. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of Ezetimibe Coadministered with Atorvastatin in 628 Patients with Primary Hypercholesterolemia. A Prospective, Randomized, Double-Blind Trial. Circulation 2003;107:2409-2415.
61. Davidson MH, McGarry T, Bettis R et al. Ezetimibe Coadministered with Simvastatin in Patients with Primary Hypercholesterolemia. J Am Coll Cardiol 2002;40:2125-2134.
62. Ballantyne CM, Blazing MA, King TR et al. Efficacy and Safety of Ezetimibe CoAdministered with Simvastatin compared with Atorvastatin in Adults with Hypercholesterolemia. Am J Cardiol 2004;93:1487-1494.
63. Pearson TA, Denke MA, McBride PE et al. A Community-Based, Randomized Trial of Ezetimibe Added to Statin Therapy to Attain NCEP ATP3 Goals for LDL Cholesterol in Hypercholesterolemic Patients: The Ezetimibe Add-On to Statin for Effectiveness (EASE) Trial. Mayo Clin Proc. 2005;80:587-595.
64. Martin J, Begg E. Reference pricing - is it in the public interest? N Z Med J 2000; 113:422-425.
65. Swinburn B, Milne R, Richards M, Begg E, Foote S, Jackson R. Reimbursement of pharmaceuticals in New Zealand: Comments on PHARMAC's processes. N Z Med J 2000; 113:425-427.
66. Bosanquet N. PHARMAC Mark 2: Towards agreed solutions? N Z Med J 2000;113:409-410.
67. Begg E, Sidwell A, Gardiner S, Nicholls G, Scott R. The sorry saga of the statins in New Zealand - pharmacopolitics versus patient care. N Z Med J 2003; 116(1170). URL: http://www.nzma.org.nz/journal/116-1170/360/